Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase

被引:110
作者
Alli, Elizabeth [1 ]
Sharma, Vandana B. [1 ]
Sunderesakumar, Preethi [1 ]
Ford, James M. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Med Oncol, Stanford, CA 94305 USA
关键词
ESTROGEN-RECEPTOR; CELL-LINES; IMMUNOHISTOCHEMICAL MARKERS; PROGESTERONE-RECEPTOR; MOLECULAR PORTRAITS; BRCA1; MUTATIONS; P53; TUMOR; PHENOTYPE; DEFICIENT;
D O I
10.1158/0008-5472.CAN-08-4016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Subtypes of breast cancer that represent the two major types of epithelial cells in the breast (luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basal-like subtype, which include the majority of hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, i.e., they lack expression of estrogen receptor-a and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may also be exploited for therapeutic purposes. We analyzed repair of oxidative DNA damage by the base-excision repair (BER) pathway, which when aberrant leads to genomic instability and breast carcinogenesis, in cell lines that represent the different subtypes of breast cancer and in the presence of BRCA1 deficiency. We found that basal-like and BRCA1-mutated breast cancer cells were defective in BER of oxidative DNA damage, and that this defect conferred sensitivity to inhibition of poly(ADP-ribose) polymerase, a DNA repair enzyme. The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness. [Cancer Res 2009;69(8):3589-96]
引用
收藏
页码:3589 / 3596
页数:8
相关论文
共 51 条
[1]   Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents [J].
Achanta, G ;
Huang, P .
CANCER RESEARCH, 2004, 64 (17) :6233-6239
[2]   A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].
Ashworth, Alan .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790
[3]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[4]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[5]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[6]   The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity [J].
Chatterjee, A ;
Mambo, E ;
Osada, M ;
Upadhyay, S ;
Sidransky, D .
FASEB JOURNAL, 2005, 19 (13) :112-+
[7]  
Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO
[8]  
2-I
[9]  
Collins AR, 1996, ENVIRON HEALTH PERSP, V104, P465, DOI 10.1289/ehp.96104s3465
[10]   p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours [J].
Crook, T ;
Brooks, LA ;
Crossland, S ;
Osin, P ;
Barker, KT ;
Waller, J ;
Philp, E ;
Smith, PD ;
Yulug, I ;
Peto, J ;
Parker, G ;
Allday, MJ ;
Crompton, MR ;
Gusterson, BA .
ONCOGENE, 1998, 17 (13) :1681-1689